AR075366A1 - Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa - Google Patents

Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa

Info

Publication number
AR075366A1
AR075366A1 ARP100100325A ARP100100325A AR075366A1 AR 075366 A1 AR075366 A1 AR 075366A1 AR P100100325 A ARP100100325 A AR P100100325A AR P100100325 A ARP100100325 A AR P100100325A AR 075366 A1 AR075366 A1 AR 075366A1
Authority
AR
Argentina
Prior art keywords
alkyl
halo
substituents
optionally substituted
cycloalkyl
Prior art date
Application number
ARP100100325A
Other languages
English (en)
Original Assignee
Ortho Mcneil Janssen Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Janssen Pharm filed Critical Ortho Mcneil Janssen Pharm
Publication of AR075366A1 publication Critical patent/AR075366A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos segun la presente resultan de utilidad como moduladores de la gamma secreta. También se refiere a los procedimientos para elaborar tales compuestos, a composiciones farmacéuticas que comprenden dichos compuestos a modo de ingrediente activo, así como al uso de dichos compuestos como medicamento. Reivindicacion 1: Un compuesto de la formula (1) o una forma estereoisomérica de éste, donde Het1 es un heterociclo aromático de 5 o 6 miembros que tiene la formula (2), (3), (4), (5) o (6); R0 es H o alquilo C1-4; R1 es H, alquilo C1-4 o alquil C1-4-oxialquilo C1-4; R2 es alquilo C1-4; X es O o S; G1 es CH o N; G2 es CH, N o C sustituido con alquilo C1-4; siempre que G1 y G2 no sean simultáneamente N; G3 es CH o N; R10a y R10b son, cada uno de manera independiente, hidrogeno o alquilo C1-4; A1 es CR3 o N; donde R3 es H, halo o alquil C1-4oxi; cada uno de A2, A3 y A4 es, de manera independiente, CH, CF o N; siempre que un máximo de dos de A1, A2, A3 y A4 sean N; Het2 es un heterociclo aromático bicíclico de 9 miembros que tiene la formula (7) o (8); Z1 es CH o N; Z2 es CR4a o N; Z3 es CH o N; siempre que como máximo uno de Z1, Z2 y Z3 sea N; Y1 es CH o N; Y2 es CR4b o N; Y3 es CH o N; siempre que como máximo uno de Y1, Y2 e Y3 sea N; R4a es H; halo; alquil C1-4oxi; ciano; cicloalquilo C3-7; alquil C1-4carbonilo; alquil C1-4oxicarbonilo o alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo y amino; R4b es H; halo; alquil C1-4oxi; ciano; cicloalquilo C3-7 o alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo y amino; R5 es H; halo; ciano; alquil C1-4oxi; alquenilo C2-6 o alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en alquil C1-4oxi y halo; R6a es alquilo C2-6 sustituido con uno o más sustituyentes de halo; alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en piperidinilo, Ar, alquil C1-6oxi, tetrahidropiranilo, cicloalquil C3-7oxi y cicloalquilo C3-7; cicloalquilo C3-7; alquil C1-4carbonilo; tetrahidropiranilo; Ar; R8R9N-carbonilo o CH2-O-Ar; R6b es alquilo C2-6 sustituido con uno o más sustituyentes de halo; alquilo C1-4 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en piperidinilo, Ar, alquil C1-6oxi, tetrahidropiranilo, cicloalquil C3-7oxi y cicloalquilo C3-7; cicloalquilo C3-7; cicloalquilo C3-7 sustituido con uno o más sustituyentes de fenilo opcionalmente sustituido con uno o más sustituyentes de halo; piperidinilo; morfolinilo; pirrolidinilo; NR8R9 tetrahidropiranilo; O-Ar; alquil C1-6oxi; alquil C1-6tio; Ar; CH2-O-Ar; S-Ar; NCH3-Ar o NH-Ar; donde cada piperidinilo, morfolinilo y pirrolidinilo puede estar opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en alquilo C1-4, alquenilo C2-6, alquil C1-4carbonílo, halo, y alquil C1-4oxicarbonilo; donde cada Ar es, de manera independiente, fenilo opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo, alquil C1-4oxi, ciano, NR8R9, morfolinilo, alquilo C1-4 y alquilo C1-4 sustituido con uno o más sustituyentes de halo; piridinilo opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo, alquil C1-4oxi, ciano, alquilo C1-4 y alquilo C1-4 sustituido con uno o más sustituyentes de halo; oxazolilo opcionalmente sustituido con uno o más sustituyentes de alquilo C1-4; o tienilo opcionalmente sustituido con uno o más sustituyentes de halo; cada R8 es, de manera independiente, H o alquilo C1-4; cada R9 es, de manera independiente, H o alquilo C1-4; R7 es H, alquilo C1-6 opcionalmente sustituido con uno o más sustituyentes, cada uno de los cuales se selecciona -de manera independiente- del grupo que consiste en halo, fenilo, y alquil C1-4oxi; o una sal de adicion farmacéuticamente aceptable o solvato de aquél.
ARP100100325A 2009-02-06 2010-02-05 Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa AR075366A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09152254 2009-02-06

Publications (1)

Publication Number Publication Date
AR075366A1 true AR075366A1 (es) 2011-03-30

Family

ID=40756688

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100325A AR075366A1 (es) 2009-02-06 2010-02-05 Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa

Country Status (20)

Country Link
US (2) US8946426B2 (es)
EP (1) EP2393804B1 (es)
JP (1) JP5576403B2 (es)
KR (1) KR20110113197A (es)
CN (1) CN102325765B (es)
AP (1) AP2011005779A0 (es)
AR (1) AR075366A1 (es)
AU (1) AU2010211109B2 (es)
BR (1) BRPI1008473A2 (es)
CA (1) CA2748862A1 (es)
EA (1) EA019685B1 (es)
ES (1) ES2481715T3 (es)
IL (1) IL214425A (es)
MX (1) MX2011008335A (es)
NZ (1) NZ593951A (es)
SG (1) SG173510A1 (es)
TW (1) TWI496780B (es)
UA (1) UA106360C2 (es)
WO (1) WO2010089292A1 (es)
ZA (1) ZA201105788B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
EP2367826A4 (en) 2008-11-06 2012-07-04 Astrazeneca Ab MODULATORS OF THE PROTEIN -AMYLOID
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
CA2784769A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators
CN102869359A (zh) * 2010-03-17 2013-01-09 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶和嘌呤化合物、组合物和使用方法
US8697708B2 (en) 2010-09-15 2014-04-15 F. Hoffmann-La Roche Ag Azabenzothiazole compounds, compositions and methods of use
WO2012066061A1 (en) 2010-11-19 2012-05-24 F. Hoffmann-La Roche Ag Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
MX2013010970A (es) 2011-03-24 2013-10-17 Cellzome Ltd Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa
CA2852939A1 (en) * 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
US9957271B2 (en) 2011-10-20 2018-05-01 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
CN104136431B (zh) 2011-12-21 2017-03-15 小野药品工业株式会社 作为凝血因子XIa抑制剂的吡啶酮和嘧啶酮衍生物
JP6106745B2 (ja) 2012-05-16 2017-04-05 ヤンセン ファーマシューティカルズ，インコーポレーテッド （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
FR2993564B1 (fr) 2012-07-20 2014-08-22 Metabrain Res Derives d'imidazopyridine utiles dans le traitement du diabete
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
AU2013366668B2 (en) 2012-12-20 2017-07-20 Janssen Pharmaceutica Nv Novel tricyclic 3,4-dihydro-2H-pyrido[1,2-alpha]pyrazine -1,6-dione derivatives as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
JP6072308B2 (ja) * 2013-02-21 2017-02-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノンｉｉ
WO2014127815A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim International Gmbh Dihydropteridinones i
EP2818472A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CA2948589A1 (en) 2014-05-23 2015-11-26 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
EP3253755B1 (en) 2015-02-03 2020-08-26 Pfizer Inc Novel cyclopropabenzofuranyl pyridopyrazinediones
SI3472160T1 (sl) 2016-06-16 2021-07-30 Janssen Pharmaceutica Nv Biciklični derivati bicikličnega piridina, pirazina in pirimidina, kot zaviralci PI3K beta
EP3475279B1 (en) 2016-06-27 2021-07-14 F. Hoffmann-La Roche AG Triazolopyridines as gamma-secretase modulators
ES2943264T3 (es) 2016-11-01 2023-06-12 Nihon Nohyaku Co Ltd Compuesto de quinolina que tiene un grupo oxima, N-óxido o sal de los mismos, insecticida agrícola y hortícola que comprende el mismo y método para su uso
BR112019024322A2 (pt) 2017-05-22 2020-06-16 F. Hoffmann-La Roche Ag Compostos e composições terapêuticos e métodos de uso dos mesmos
CN108440509B (zh) * 2018-04-23 2021-03-02 山西大同大学 一种阿托伐他汀钙中间体制备的方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
WO1997003067A1 (en) 1995-07-13 1997-01-30 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
JP2003502313A (ja) 1999-06-10 2003-01-21 ワーナー−ランバート・カンパニー イソインドリン誘導体を用いたアミロイドタンパク質凝集抑制およびアミロイド付着部画像化の方法
AU5702201A (en) 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
WO2001087845A2 (en) 2000-05-15 2001-11-22 Fujisawa Pharmaceutical Co., Ltd. N-containing heterocyclic compounds and their use as 5-ht antagonists
DE10109867A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Verwendung von Triazolverbindungen zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
DE10238002A1 (de) 2002-08-20 2004-03-04 Merck Patent Gmbh Benzimidazolderivate
AU2004215679A1 (en) 2003-02-27 2004-09-10 F. Hoffmann-La Roche Ag CCR-3 receptor antagonists
CN1787822A (zh) * 2003-05-14 2006-06-14 托里派因斯疗法公司 化合物及其在调节淀粉样蛋白β中的用途
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
KR100742014B1 (ko) 2003-08-14 2007-07-23 에프. 호프만-라 로슈 아게 Ｇａｂａ계 조절제
JP2007527904A (ja) 2004-03-08 2007-10-04 プロシディオン・リミテッド グリコーゲンホスホリラーゼ阻害剤としてのピロロピリジン−２−カルボン酸ヒドラジド化合物
WO2005115990A1 (ja) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
ZA200609845B (en) * 2004-05-26 2010-02-24 Eisai R&D Man Co Ltd Cinnamide compound
CN100577657C (zh) 2004-10-26 2010-01-06 卫材R&D管理有限公司 肉桂酰胺化合物的无定形物
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
JP2009508929A (ja) 2005-09-22 2009-03-05 サノフイ−アベンテイス Ｃｃｒ３受容体リガンドとしてのアミノ−アルキル−アミド誘導体
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2007043786A1 (en) 2005-10-10 2007-04-19 Seiyang Yang Dynamic-based verification apparatus for verification from electronic system level to gate level, and verification method using the same
JP4987873B2 (ja) 2005-10-11 2012-07-25 ケムチュア コーポレイション 二芳香族アミン
US20090163482A1 (en) 2006-03-13 2009-06-25 Mchardy Stanton Furst Tetralines antagonists of the h-3 receptor
GB0606774D0 (en) 2006-04-03 2006-05-10 Novartis Ag Organic compounds
US7893058B2 (en) 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
WO2008065199A1 (en) 2006-12-01 2008-06-05 Galapagos N.V. Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
EP2061771A1 (en) 2006-12-12 2009-05-27 Schering Corporation Aspartyl protease inhibitors containing a tricyclic ring system
CN101631786A (zh) 2006-12-20 2010-01-20 先灵公司 新颖的jnk抑制剂
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP2010518083A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション ピペリジン誘導体
RU2009144998A (ru) 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
CN101675045B (zh) 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
US20110053918A1 (en) 2007-06-29 2011-03-03 Zhaoning Zhu Gamma secretase modulators
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
US8518975B2 (en) 2007-09-06 2013-08-27 Merck Sharp + Dohme Corp. Gamma secretase modulators
GB0720444D0 (en) 2007-10-18 2007-11-28 Glaxo Group Ltd Novel compounds
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
WO2009076352A1 (en) 2007-12-11 2009-06-18 Schering Corporation Gamma secretase modulators
CN101952275B (zh) 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
EP2356115A1 (en) 2008-11-06 2011-08-17 Schering Corporation Gamma secretase modulators
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
AU2009322774A1 (en) 2008-12-03 2011-06-30 Via Pharmaceuticals, Inc Inhibitors of diacylglycerol acyltransferase
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
CA2753696A1 (en) 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
EP2403835A1 (en) 2009-03-03 2012-01-11 Pfizer Inc. Novel phenyl imidazoles and phenyl triazoles as gamma-secretase modulators
US20110299830A1 (en) 2009-03-16 2011-12-08 Panasonic Corporation Application running device
KR20120028869A (ko) 2009-04-27 2012-03-23 하이 포인트 파마슈티칼스, 엘엘씨 β-세크레타제 억제제로서 치환된 이미다조［1,2-Ａ］피리딘 유도체, 약제학적 조성물, 및 사용 방법
JP5559309B2 (ja) 2009-05-07 2014-07-23 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド γ分泌酵素調節物質としての新規置換インダゾールおよびアザインダゾール誘導体
JP2010274429A (ja) 2009-05-26 2010-12-09 Ihi Corp アライメントステージ
KR20120050450A (ko) 2009-07-15 2012-05-18 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절제로서의 치환된 트리아졸 및 이미다졸 유도체
CA2784769A1 (en) 2010-01-15 2011-07-21 Janssen Pharmaceuticals, Inc. Novel substituted triazole derivatives as gamma secretase modulators
MX2013010970A (es) 2011-03-24 2013-10-17 Cellzome Ltd Novedosos derivados de triazolil piperazina y triazolil piperidina sustituidos como moduladores de gamma-secretasa.
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
ES2555167T3 (es) 2011-07-15 2015-12-29 Janssen Pharmaceuticals, Inc. Nuevos derivados de indol sustituidos como moduladores de gamma secretasa

Also Published As

Publication number Publication date
EA019685B1 (ru) 2014-05-30
BRPI1008473A2 (pt) 2019-04-02
CA2748862A1 (en) 2010-08-12
US20110281881A1 (en) 2011-11-17
CN102325765B (zh) 2014-12-24
JP2012516870A (ja) 2012-07-26
IL214425A (en) 2015-07-30
NZ593951A (en) 2013-01-25
SG173510A1 (en) 2011-09-29
WO2010089292A1 (en) 2010-08-12
AP2011005779A0 (en) 2011-08-31
ZA201105788B (en) 2015-06-24
KR20110113197A (ko) 2011-10-14
TWI496780B (zh) 2015-08-21
EA201171008A1 (ru) 2012-02-28
TW201040176A (en) 2010-11-16
AU2010211109A1 (en) 2011-07-21
AU2010211109B2 (en) 2014-11-27
IL214425A0 (en) 2011-09-27
US20150094311A1 (en) 2015-04-02
CN102325765A (zh) 2012-01-18
UA106360C2 (ru) 2014-08-26
EP2393804B1 (en) 2014-04-16
ES2481715T3 (es) 2014-07-31
EP2393804A1 (en) 2011-12-14
JP5576403B2 (ja) 2014-08-20
MX2011008335A (es) 2011-09-06
US8946426B2 (en) 2015-02-03

Similar Documents

Publication Publication Date Title
AR075366A1 (es) Compuestos heterociclicos biciclicos sustituidos como modulares de la gamma secretasa
PH12020550552A1 (en) Inhibitors of hepatitis c virus
DOP2018000187A (es) Derivados de pirazolo[1,5-a]pirazin-4-ilo
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR087182A1 (es) DERIVADOS DE INDOL SUSTITUIDOS COMO MODULADORES DE g SECRETASA
AR102204A1 (es) Compuestos derivados de amino-alquilbenzotiazepinas
WO2015200677A8 (en) Prmt5 inhibitors and uses thereof
MX2014011829A (es) Compuestos de piridinilideno n-sustituidos y derivados para combatir plagas de animales.
MY187617A (en) Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
MX354175B (es) Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria.
MX2013011551A (es) Compuestos y derivados hetero - biciclicos n - sustituidos para combatir las pestes en animales.
AR084849A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
AR062526A1 (es) DERIVADOS DE 4-(3-METILMORFOLIN-4-IL)PIRIMIDINA Y MORFOLIN-4-IL-PIRIMIDINA COMO INHIBIDORES DE MTOR QUINASA Y PI3K, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y EL USO DE LOS MISMOS EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER.
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
AR079904A1 (es) Derivados de triazol sustituidos como moduladores de la gamma secretasa
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
AR074771A1 (es) Derivados de imidazol biciclicos sustituidos como moduladores de gamma secretasa
AR085549A1 (es) DERIVADOS TRIAZOLIL PIPERAZINA Y TRIAZOLIL PIPERIDINA SUSTITUIDOS COMO MODULADORES DE g SECRETASA
JO3115B1 (ar) مركبات بيريدازينون واستخدامها كمثبطات daao
MX2014011752A (es) Compuestos heterobiciclicos n-sustituidos y derivados para combatir plagas de animales ii.
MX2014011995A (es) Compuestos de furanona heterobicíclicos n-sustituidos y derivados para combatir plagas de animales.
AR091490A1 (es) Antagonistas de iap
CO6460737A2 (es) N-((1r,2s,5r)-5-(tert -butilamino)-2-((s)-3-(7-tert-butilpirazolo[1.5-a][1.3.5]traizin -4-ilamino)-2-oxopirrolidin-1-il)ciclohexil)acetamida, un modulador dual de la actividad del receptor de quimiocinas, formas cristalinas y procesos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal